Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 201–300 of 892
Emerging therapies for mitochondrial disorders
Nightingale, H., Pfeffer, G., Bargiela, D., Horváth, R., & Chinnery, P. F. (2016) · Brain · doi:10.1093/brain/aww081 · Cited by 78
Gene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Whole Brain Imaging with Serial Two-Photon Tomography
Amato, S. P., Pan, F., Schwartz, J., & Ragan, T. M. (2016) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00031 · Cited by 67
“However, while the repertoire of AAV serotypes demonstrating BBB penetrance has significantly expanded (Bourdenx et al., 2014), most clinical applications have been limited to the AAV2 (Mingozzi and High, 2011).”
BackgroundRetinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
“that AAV vectors can integrate into the host genome, no major insertional mutagenesis issues have been reported [12–14].”
BackgroundTriboelectric nanogenerators for self-powered drug delivery
Li, X., Tat, T., & Chen, J. (2021) · Trends in Chemistry · doi:10.1016/j.trechm.2021.04.009 · Cited by 69
Negishi, Y., Yamane, M., Kurihara, N., Endo-Takahashi, Y., Sashida, S., Takagi, N., Suzuki, R., & Maruyama, K. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7030344 · Cited by 68
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67
Yoon, H. H., Ye, S., Lim, S., Jo, A., Lee, H., Hong, F., Lee, S. E., Oh, S., Kim, N., Kim, K., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0025 · Cited by 72
Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00006-8 · Cited by 66
“While AAV is nonpathogenic and is not associated with the pathology of adenoviral infections, the human population has been exposed to wild-type AAV infections that establish immunity to these viruses that impacts the transduction and long-term expression using these vectors.(104) These hurdles must be overcome for tr…”
BackgroundKetzer, P., Haas, S., Engelhardt, S., Hartig, J., & Nettelbeck, D. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks734 · Cited by 70
“Adeno-associated viruses (AAVs) are further important gene therapy vectors that have recently shown encouraging results both pre-clinically and in patients for the treatment of inherited diseases (28).”
Antibody-mediated prevention and treatment of HIV-1 infection
Gruell, H., & Klein, F. (2018) · Retrovirology · doi:10.1186/s12977-018-0455-9 · Cited by 77
Chen, Q., Osada, K., Ge, Z., Uchida, S., Tockary, T. A., Dirisala, A., Matsui, A., Toh, K., Takeda, K. M., Liu, X., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.042 · Cited by 66
Mietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., & Heilbronn, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.050 · Cited by 65
Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells
Drouet, V., Ruiz, M., Zala, D., Feyeux, M., Aurégan, G., Cambon, K., Troquier, L., Carpentier, J., Aubert, S., Mérienne, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099341 · Cited by 76
“These developments have led to the initiation of several phase I/II clinical trials with adenoassociated vectors (AAV) [47]; more recently trials have started with lentiviral vectors for the treatment of adrenoleukodystrophy [48] and Parkinson’s disease [49].”
BackgroundYamashita, T., Chai, H. L., Teramoto, S., Tsuji, S., Shimazaki, K., Muramatsu, S., & Kwak, S. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302935 · Cited by 64
“Recently, clinical challenges for gene therapy have been observed when using adeno ‐ associated virus (AAV) as a vector (Lonergan et al, 2005; Mingozzi & High, 2011).”
Human Glucocorticoid Receptor β Regulates Gluconeogenesis and Inflammation in Mouse Liver
He, B., Cruz-Topete, D., Oakley, R. H., Xiao, X., & Cidlowski, J. A. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00908-15 · Cited by 62
“vector because of its safety, low immunogenicity and long-term gene transfer (19).”
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome
Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.011 · Cited by 63
“(sc)AAV and (ss)AAV vectors have been used to transduce the liver in the context of several genetic disorders.(10) To this aim, the use of (sc)AAV vectors could provide potential advantages related to the bypass of the step of double-stranded DNA (dsDNA) conversion of the vg, thus facilitating the viral transduction.”
BackgroundMethodInfluentialSelf-citationPress, A. T., Traeger, A., Pietsch, C., Mosig, A. S., Wagner, M., Clemens, M. G., Jbeily, N., Koch, N., Gottschaldt, M., Bézière, N., et al. (2014) · Nature Communications · doi:10.1038/ncomms6565 · Cited by 64
Structure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 64
“…non-pathogenic parvovirus adeno-associated virus (AAV) show great promise as gene delivery vectors due to their ability to deliver packaged foreign genes for stable and long-term protein expression in a wide range of human tissues (reviewed in (Flotte and Carter, 1995; Mingozzi and High, 2011)).”
BackgroundGlycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9
Shen, S., Bryant, K. D., Sun, J., Brown, S. M., Troupes, A., Pulicherla, N., & Asokan, A. (2012) · Journal of Virology · doi:10.1128/jvi.01155-12 · Cited by 63
“The latter are nonpathogenic, helper-dependent parvoviruses, currently being evaluated in phase I to III clinical trials as vectors for gene therapy (20).”
BackgroundHemophilia gene therapy comes of age
George, L. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009878 · Cited by 62
Strategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
Strobel, B., Duechs, M. J., Blazevic, D., Rechtsteiner, P., Braun, C., Kroker, K. S., Schmid, B., Ciossek, T., Gottschling, D., Hartig, J. S., et al. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00410 · Cited by 69
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“Although AAV, in general, has a favorable immune response pro fi le, pre-existing neutralizing antibodies (NAbs) against the capsid of natural AAV serotypes are a major concern [212–214], since they can limit patient eligibility for AAV products.”
BackgroundFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Porro, F., Bortolussi, G., Barzel, A., Caneva, A. D., Iaconcig, A., Vodret, S., Zentilin, L., Kay, M. A., & Muro, A. F. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707601 · Cited by 65
“Gene replacement mediated by adeno-associated virus (AAV) is a promising approach (Kay, 2011; Mingozzi & High, 2011; Nathwani et al , 2011).”
RNA-guided retargeting of Sleeping Beauty transposition in human cells
Kovač, A., Miskey, C., Menzel, M., Grueso, E., Gogol‐Döring, A., & Ivics, Z. (2020) · eLife · doi:10.7554/elife.53868 · Cited by 64
“The absence of viral proteins may also prevent immune reactions that are observed with adeno-associated virus (AAV)-based vectors ( Mingozzi and High, 2011 ; Hareendran et al., 2013 ).”
BackgroundZou, L., Tian, H., Guan, S., Ding, J., Gao, L., Wang, J., & Fang, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-26168-0 · Cited by 60
Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology
Kouprina, N., Tomilin, A. N., Masumoto, H., Earnshaw, W. C., & Larionov, V. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.882314 · Cited by 62
“So far, the vast majority of gene therapy clinical trials have exploited viral vectors such as retroviral, lentiviral, adenoviral and adeno-associated virus-based vectors [7-22].”
BackgroundMishra, G., Prajapat, V., & Nayak, D. (2023) · Immunology · doi:10.1111/imm.13695 · Cited by 75
“Compared with other viruses used as vaccine vectors, AAV has several advantages, including its non-pathogenic nature [81, 82], and lack of ability to induce significant pathogenicity due to the absence of viral genes [83].”
BackgroundGene doping: an overview and current implications for athletes
van der Gronde, T., de Hon, O., Haisma, H. J., & Pieters, T. (2013) · British Journal of Sports Medicine · doi:10.1136/bjsports-2012-091288 · Cited by 60
Chamorro, C., Mencía, Á., Almarza, D., Duarte, B., Büning, H., Sallach, J., Haußer, I., Río, M. D., Larcher, F., & Murillas, R. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.19 · Cited by 66
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 70
“Among them, AAV has become the most widely accepted viral vector for gene therapy in vivo due to its mild immunogenicity and good therapeutic effect in a broad range of animal models and clinical trials (163, 164).”
BackgroundPañeda, A., Lopez-Franco, E., Kaeppel, C., Unzu, C., Gil-Royo, A. G., D'Avola, D., Beattie, S. G., Olagüe, C., Ferrero, R., Sampedro, A., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.166 · Cited by 60
“AAV2 is the best characterized prototypic recombinant vector and has been employed in over 40 clinical trials (Mingozzi and High, 2011a).”
Supramolecular Assemblies of Peptides or Nucleopeptides for Gene Delivery
Wang, H., Feng, Z., & Xu, B. (2019) · Theranostics · doi:10.7150/thno.31854 · Cited by 62
“intrinsic drawbacks, including low cargo capacity, immunogenicity, and limitation in large scale production [3-7].”
BackgroundProtein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Dirren, E., Towne, C. L., Setola, V., Redmond, D. E., Schneider, B. L., & Aebischer, P. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.021 · Cited by 58
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 61
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
“Although several different gene delivery vehicles, or vectors, have been evaluated in hemophilia gene transfer clinical trials, current efforts have coalesced around the use of rAAV vectors for in vivo hepatocyte gene delivery.(4) Additional strategies are in preclinical investigation and reviewed elsewhere.”
BackgroundRational Design of Mini-Cas9 for Transcriptional Activation
Ma, D., Peng, S., Huang, W., Cai, Z., & Xie, Z. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00404 · Cited by 62
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Self-citationEndocytic processing of adeno-associated virus type 8 vectors for transduction of target cells
Liu, Y., Joo, K.-I., & Wang, P. (2012) · Gene Therapy · doi:10.1038/gt.2012.41 · Cited by 59
Zhang, C., Yao, T., Zheng, Y., Li, Z., Zhang, Q., Zhang, L., & Zhou, D. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.066 · Cited by 62
“Promising results have been obtained from Phase 1–3 trials with several diseases, including cystic fibrosis [3], retinal degenerative disorders [4-6], and hemophilia B [7-10].”
AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice
Lukashchuk, V., Lewis, K. E. A., Coldicott, I., Grierson, A. J., & Azzouz, M. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.55 · Cited by 62
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 57
“trials have proceeded in the absence of significant adverse events and some have yielded dramatic therapeutic efficacy (40).”
BackgroundBreton, C., Clark, P. M., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · BMC Genomics · doi:10.1186/s12864-020-6655-4 · Cited by 57
Chandler, R. J., Venturoni, L. E., Liao, J., Hubbard, B. T., Schneller, J. L., Hoffmann, V. J., Gordo, S., Zang, S., Ko, C., Chau, N., et al. (2020) · Hepatology · doi:10.1002/hep.31570 · Cited by 61
Strobel, B., Klauser, B., Hartig, J. S., Lamla, T., Gantner, F., & Kreuz, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.123 · Cited by 57
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“This small size allows it to be easily packaged in a recombinant adeno-associated virus, a gene therapy vector that has provided promising results for a variety of genetic disorders (18).”
BackgroundLattanzi, A., Salvagno, C., Maderna, C., Benedicenti, F., Morena, F., Kulik, W., Naldini, L., Montini, E., Martino, S., & Gritti, A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu034 · Cited by 60
“Immune responses decreasing the efficacy of the strategy and risks related to insertional mutagenesis are major hurdles associated with intracerebral GT using AAV and LV, respectively (25,26).”
BackgroundAronson, S. J., Bakker, R. S., Shi, X., Duijst, S., ten Bloemendaal, L., de Waart, D. R., Verheij, J., Ronzitti, G., Elferink, R. P. J. O., Beuers, U. H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.021 · Cited by 66
Site‐Specific Modification of Adeno‐Associated Viruses via a Genetically Engineered Aldehyde Tag
Liu, Y., Fang, Y. H., Zhou, Y., Zandi, E., Lee, C.-L., Joo, K., & Wang, P. (2012) · Small · doi:10.1002/smll.201201661 · Cited by 62
Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 93
Lim, J., Yi, H., Gao, F., Raben, N., Kishnani, P. S., & Sun, B. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.006 · Cited by 61
Wang, L.-N., Wang, Y., Lu, Y., Yin, Z.-F., Zhang, Y.-H., Aslanidi, G., Srivastava, A., Ling, C., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60003-0 · Cited by 54
Bish, L. T., Sleeper, M. M., Reynolds, C., Gazzara, J. A., Withnall, E., Singletary, G. E., Buchlis, G., Hui, D. J., High, K. A., Gao, G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.035 · Cited by 66
“, 2006), and this same rigorous ELISpot analysis continues to be used as the primary assay for detection of T cell responses in current clinical and nonhuman primate trials of AAV-mediated gene transfer for hemophilia (Mingozzi and High, 2011; Nathwani et al. 2011).”
Self-citationSong, L., Li, X., Jayandharan, G. R., Wang, Y., Aslanidi, G. V., Ling, C., Zhong, L., Gao, G., Yoder, M. C., Ling, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058757 · Cited by 54
“Recombinant vectors based on a non-pathogenic human virus, the adeno-associated virus 2 (AAV2) have been developed and shown to be safe and effective in a number of recent clinical trials [2,3].”
MethodBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationSleeping Beauty transposition: from biology to applications
Narayanavari, S. A., Chilkunda, S. S., Ivics, Z., & Izsvák, Z. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1237935 · Cited by 62
“AAV vectors have been shown to be one of the most promising vectors for therapeutic gene delivery, and were involved in several clinical trials, primarily in slowly dividing cells (Mingozzi & High, 2011).”
BackgroundIn Situ Modification of Tissue Stem and Progenitor Cell Genomes
Goldstein, J. M., Tabebordbar, M., Zhu, K., Wang, L. D., Messemer, K. A., Peacker, B. L., Kakhki, S. A., Gonzalez-Celeiro, M., Shwartz, Y., Cheng, J. K. W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.105 · Cited by 55
“This issue has been extensively reviewed elsewhere, and it has not precluded clinical testing of AAV-based therapeutics for various diseases in human populations (Colella et al., 2017; Mingozzi and High, 2011).”
Wang, J., Yang, J., Li, D., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188454 · Cited by 57
The roles of traditional Chinese medicine in gene therapy
Ling, C., Wang, L., Wang, Y., Zhang, Y., Yin, Z.-F., Wang, M., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60019-4 · Cited by 54
Controlled release strategies for rAAV-mediated gene delivery
Rey‐Rico, A., & Cucchiarini, M. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.015 · Cited by 53
Sharma, V. D., Lees, J., Hoffman, N. E., Brailoiu, E., Madesh, M., Wunder, S. L., & Ilies, M. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4005035 · Cited by 53
Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy
Matteo, M. D., Samara-Kuko, E., Ward, N. J., Waddington, S. N., McVey, J. H., Chuah, M., & VandenDriessche, T. (2014) · Molecular Therapy · doi:10.1038/mt.2014.131 · Cited by 57
Peptide Vectors for Gene Delivery: From Single Peptides to Multifunctional Peptide Nanocarriers
de Raad, M., Teunissen, E. A., & Mastrobattista, E. (2014) · Nanomedicine · doi:10.2217/nnm.14.90 · Cited by 52
Darvishi, B., Farahmand, L., & Majidzadeh‐A, K. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.03.007 · Cited by 53
“Viral and non-viral vehicles have both been applied for systemic delivery of siRNAs in the clinic.(31,32) However, several limitations have been found in association with the administration of viruses as vehicles for gene-based therapeutic agents, including the potency for carcinogenesis, limited DNA packaging capabil…”
Muik, A., Reul, J., Friedel, T., Muth, A., Hartmann, K. P., Schneider, I. C., Münch, R. C., & Buchholz, C. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.032 · Cited by 54
Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy
Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.006 · Cited by 59
“Especially the emergence of AAV in gene therapy, many serotypes of AAV with specific tropisms for different tissues increase organs specificities of genome editing elements [101].”
BackgroundBakhshandeh, B., Soleimani, M., Hafizi, M., & Ghaemi, N. (2012) · Cytotechnology · doi:10.1007/s10616-012-9430-9 · Cited by 52
Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system
Li, Q., Su, J., Liu, Y., Jin, X., Zhong, X., Mo, L., Wang, Q., Deng, H., & Yang, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.005 · Cited by 55
François, A., Bouzelha, M., Lecomte, E., Broucque, F., Penaud-Budloo, M., Adjali, O., Moullier, P., Blouin, V., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.004 · Cited by 50
RGD peptide-based lipids for targeted mRNA delivery and gene editing applications
Qin, J., Xue, L., Gong, N., Zhang, H., Shepherd, S. J., Haley, R. M., Swingle, K. L., & Mitchell, M. J. (2022) · RSC Advances · doi:10.1039/d2ra02771b · Cited by 47
In the business of base editors: Evolution from bench to bedside
Porto, E. M., & Komor, A. C. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002071 · Cited by 57
Gene therapy: principles, challenges and use in clinical practice
Ay, C., & Reinisch, A. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02368-8 · Cited by 61
“Most current in vivo gene therapies target the patient’s liver and can be applied intravenously [15].”
Advances and challenges in gene‐based approaches for osteoarthritis
Madry, H., & Cucchiarini, M. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2741 · Cited by 55
“Nevertheless, rAAV became a preferred tool for experimental OA settings in vivo [102,122,123] and for clinical applications [24,124–126].”
MethodInside Job: Methods for Delivering Proteins to the Interior of Mammalian Cells
Bruce, V. J., & McNaughton, B. R. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.014 · Cited by 57
“(factor IX or FIX) (High et al., 2014; Mingozzi and High, 2011).”
Donadon, I., Pinotti, M., Rajkowska, K., Pianigiani, G., Barbon, E., Morini, E., Motaln, H., Rogelj, B., Mingozzi, F., Slaugenhaupt, S. A., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy151 · Cited by 51
Self-citationA siRNA-induced peptide co-assembly system as a peptide-based siRNA nanocarrier for cancer therapy
Li, W., Wang, D., Shi, X., Li, J., Ma, Y., Wang, Y., Li, T., Zhang, J., Zhao, R., Yu, Z., et al. (2018) · Materials Horizons · doi:10.1039/c8mh00392k · Cited by 50
In vivo epigenome editing and transcriptional modulation using CRISPR technology
Lau, C., & Suh, Y. (2018) · Transgenic Research · doi:10.1007/s11248-018-0096-8 · Cited by 57
“TALE domain has also been fused to the DNMT3A-Dnmt3L for stably silencing target gene expression by inducing DNA methylation and reducing chromatin accessibil- ity at the promoters (Mlambo et al. 2018).”
Gallego, I., Villate-Beitia, I., Martínez-Navarrete, G., Menéndez, M., López-Méndez, T., Soto-Sánchez, C., Zárate, J., Puras, G., Fernández, E., & Pedraz, J. L. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.12.018 · Cited by 50
Suzuki, M., Bertin, T. K., Rogers, G. L., Cela, R. G., Zolotukhin, I., Palmer, D. J., Ng, P., Herzog, R. W., & Lee, B. (2013) · Molecular Therapy · doi:10.1038/mt.2012.277 · Cited by 49
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 48
Self-citationFuture of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 58
“The continued identification of mutations causative for Mendelian conditions means novel gene replacement strategies will be attempted, leading to continued clinical success stories.(8) However, this review will focus on non-traditional uses for rAAV vectors (Fig.”
Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
Fraldi, A., Serafini, M., Sorrentino, N. C., Gentner, B., Aiuti, A., & Bernardo, M. E. (2018) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-018-0565-y · Cited by 57
Peptide-based nanomaterials and their diverse applications
Das, T. N., Ramesh, A., Ghosh, A. P., Moyra, S., Maji, T. K., & Ghosh, G. (2024) · Nanoscale Horizons · doi:10.1039/d4nh00371c · Cited by 51
Ruzo, A., García, M., Ribera, A., Villacampa, P., Haurigot, V., Marcó, S., Ayuso, E., Anguela, X. M., Roca, C., Agudo, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.220 · Cited by 62
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Self-citationShin, J.-H., Yue, Y., Srivastava, A., Smith, B., Lai, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.147 · Cited by 47
Bortolanza, S., Nonis, A., Sanvito, F., Maciotta, S., Sitia, G., Wei, J., Torrente, Y., Serio, C. D., Chamberlain, J. R., & Gabellini, D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.153 · Cited by 57
Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy
Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S. A., Ulus, H., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.14 · Cited by 49
Benskey, M. J., Kuhn, N. C., Galligan, J. J., Garcia, J., Boye, S. E., Hauswirth, W. W., Mueller, C., Boye, S. L., & Manfredsson, F. P. (2015) · Molecular Therapy · doi:10.1038/mt.2015.7 · Cited by 47
A universal system to select gene-modified hepatocytes in vivo
Nygaard, S. C., Barzel, A., Haft, A., Major, A. M., Finegold, M. J., Kay, M. A., & Grompe, M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8166 · Cited by 48
Penaud-Budloo, M., Lecomte, E., Guy-Duché, A., Saleun, S., Roulet, A., Lopez-Roques, C., Tournaire, B., Cogné, B., Léger, A., Blouin, V., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.185 · Cited by 49
van Lieshout, L. P., Soule, G., Sorensen, D., Frost, K. L., He, S., Tierney, K. J., Safronetz, D., Booth, S. A., Kobinger, G., Qiu, X., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix644 · Cited by 49
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
Martinez-Navío, J. M., Fuchs, S. P., Mendes, D. E., Rakasz, E. G., Gao, G., Lifson, J. D., & Desrosiers, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00449 · Cited by 51
Ling, C., Wang, Y., Lu, Y., Wang, L., Jayandharan, G. R., Aslanidi, G. V., Li, B., Cheng, B., Ma, W., Lentz, T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02581-14 · Cited by 47
Nieto, K., Stahl-Hennig, C., Leuchs, B., Müller, M., Gissmann, L., & Kleinschmidt, J. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.202 · Cited by 46
“In clinical trials, adenoassociated virus (AAV) has demonstrated great potential as a DNA-delivery vector to treat serious human diseases (for review, see Mingozzi and High, 2011).”
BackgroundMiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3
Wang, Y., Zhu, H., Zhang, Z., Ren, F., & Hu, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0628-6 · Cited by 48
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.